Neurocrine Shares Earlier Spiked 1.8% Following Trader Circulation Of ClinicalTrials.gov Doc, Price Soon After Pared Gains; Baird's Brian Skorney Tells Benzinga 'This Study Really Shouldn't Have Any Impact On Outlook For NBIX'
Benzinga Newsdesk